Specifically, tumors from SA-treated subjects demonstrated markedly diminished PD-L1 immunoreactivity across multiple tumor regions, including both the tumor core and invasive margins, when compared to PBS-treated controls and PD-L1 antibody-treated groups. The gene discussed is CD274; the disease is neoplasm.